Clinical Role - Specialty Pharmacy

Pharmacy Times® is a leader in providing expert insights and clinical updates to specialty pharmacists and reaches more than 200,000 pharmacy professionals in total.

Adding atezolizumab (Tecentriq) to bevacizumab (Avastin) and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.
More than half of high-risk patients with resected, stage III BRAF V600-mutated melanoma who were treated with dabrafenib and trametinib were alive and relapse-free at 5 years.
The COVID-19 pandemic will be felt in the oncology space long after the pandemic is over, study shows. 

The CheckMate 9ER trial took 2 drugs used as monotherapies in the second line of therapy, nivolumab and cabozantinib, and combined them for use as a first-line treatment against standard of care, sunitinib.
More targeted therapies often have better toxicity profiles, allowing patients to remain adherent for longer.
Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) showed early antitumor activity and tolerability in previously treated triple-negative breast cancer patients with advanced solid tumors.
Trial shows that olaparib, a poly ADP ribose polymerase inhibitor that is the first cancer drug to target an inherited genetic fault, can be used successfully to treat prostate cancers with a weakness in the ability to repair damaged DNA.
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
Recent studies have analyzed how individuals with autoimmune conditions prescribed specialty medications may be affected by the COVID-19 pandemic.
Digital health tools were a major theme during the first-ever NASP Challenge, comprising 4 of the 5 finalists.
September has been designated as National Sickle Cell Awareness Month for the continued fostering of education surrounding sickle cell disease management.
There were a number of FDA approvals in 2019 that were either the first new therapies or first in class approved for certain conditions, and the specialty pipeline is continuing to grow at a rapid pace.